



Press release

August 24th, 2020

Regulatory approvals for sepsis prediction study

AlgoDx, which focuses on supporting disease prediction with machine learning algorithms, today announces the obtention of regulatory approval from the Swedish Medical Products Agency (MPA) to start a sepsis prediction study at an Intensive Care Unit (ICU) in Sweden. The study has previously been approved by the National Ethics Committee through an expedited review for research that has potential to provide benefit for the treatment and prevention of Covid-19, given that sepsis is a common complication in connection with Covid-19.

- We have had a very constructive dialogue with the MPA and been able to justify the design of our clinical study that will include a vulnerable population consisting of intensive care patients, where our sepsis prediction software addresses an unmet medical need. This study is the largest randomized clinical trial with a sepsis prediction algorithm ever conducted and is designed to clinically validate our product. We hope to be able to demonstrate that our technology can improve patient outcomes at ICUs, says David Becedas, Director Clinical Research.

About Sepsis and AlgoDx ExPRESS™

Sepsis can lead to multiple organ damage and is a potentially life-threatening condition that occurs when the body's response to fight an infection is out of balance. Sepsis affects more than 30 million people worldwide yearly, potentially leading to 6 million deaths. In sepsis treatment, the time factor is critical; where the cornerstones of intervention are early and appropriate antibiotics together with source control and fluid administration. Current detection methods for sepsis are incapable of early prediction. AlgoDx's solution lies in the deployment of the machine learning based prediction algorithm AlgoDx ExPRESS™ that, using only parameters that are routinely collected on Electronic Medical Records, accurately predicts sepsis in hospitalized patients.

About AlgoDx

AlgoDx is a privately-owned company associated with Uppsala University. The company's mission is to bring clinically validated machine learning algorithms that saves lives and improves cost-effectiveness in healthcare to market.

AlgoDx AB, Bastugatan 12B, Stockholm, algodx.com

Press contact: David Becedas, Director Clinical Research. Tel: +46 72 232 83 48. Mail: david.becedas@algodx.com